Applied Microbiology Inc. (NASDAQ:AMBI) announced Tuesdaythat the University of Maryland, College Park (UMCP), has beenissued U.S. Patent No. 5,218,101 for the recombinant expressionand production of novel anti-microbial proteins including nisinand subtilin.
Applied Microbiology has an exclusive license to thetechnology, developed by Norman Hansen at the university.Rights to a related technology, also developed by Hansen, whichis covered under a pending U.S. patent application, wereincluded in the exclusive license to Applied Microbiology ofNew York.
The issued patent covers the cloning and use of the nisin genefor producing Ambicin N and Nisaplin, Applied Microbiology'scurrent products, as well as for second-generation products.
(c) 1997 American Health Consultants. All rights reserved.